Recent evidence identifies S-nitrosylation of Pyruvate Kinase M2 (PKM2) as a specific driver of cardiac fibrosis, suggesting that activating PKM2 with drugs like mitapivat could provide a long-sought therapeutic approach for heart failure patients.